Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
4Customers
3Debt Items
0Related Chains
Source-Backed Evidence Depth
Castle Biosciences, Inc. (CSTL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
2Distinct source URLs
8High confidence
0.829Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Castle Biosciences, Inc. Suppliers
Ticker
Name
Confidence
Evidence
SCIBASE
SCIBASE
90%
SciBase is entitled to royalties on our product sales, a mark-up on product sales to us, and a milestone payment upon achieving specified sales thresholds.
NORIDIAN-HEALTHCARE-SOLUTIONS-LLC
NORIDIAN-HEALTHCARE-SOLUTIONS-LLC
80%
The MAC responsible for administering claims for laboratory services located in Arizona is Noridian Healthcare Solutions, LLC ("Noridian").
Castle Biosciences, Inc. Customers
Ticker
Name
Confidence
Evidence
MEDICARE
MEDICARE
90%
Our revenue from patients covered by Medicare as a percentage of total revenue, was 47 % for the year ended December 31, 2024.
COMMERCIAL-PAYOR
COMMERCIAL-PAYOR
85%
Additionally, there was a commercial payor from which 15 % of our revenue from patients was derived for the year ended December 31, 2024.
CAPITAL-RESOURCES
CAPITAL-RESOURCES
62%
dditional third-party payors and increase our reimbursement rate for tests performed. Cost of Sales (exclusive of amortization of acquired intangible assets) The components of our cost of sales are m…
FAROS-ACA-RE-LLC
FAROS-ACA-RE-LLC
62%
(1) $ 41,105 $ 62,962 Non-Dermatologic (2) 42,574 25,026 Total net revenues $ 83,679 $ 87,988 (1) Consists of DecisionDx-Melanoma, DecisionDx-SCC and MyPath Melanoma. (2) Consists of TissueCypher, De…
Castle Biosciences, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CSTL-DEBT-8893
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
CSTL-DEBT
Debt stack $10.1M
90%
Market cache reports total debt of $10.1M.
CSTL-DEBT-8892
Warrants outstanding: 403142
90%
xbrl warrant detail from xbrl 2020-12-31.
Castle Biosciences, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Castle Biosciences, Inc..
Castle Biosciences, Inc. Ownership
Holder
Name
Confidence
Evidence
CSTL-OWNER-BLACKROCK-INC
BlackRock, Inc.
90%
13F overlay lists BlackRock, Inc. as top holder; 190 tracked holders.
Castle Biosciences, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
